Wan-Ching Yen

2.3k total citations
47 papers, 1.3k citations indexed

About

Wan-Ching Yen is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Wan-Ching Yen has authored 47 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 23 papers in Oncology and 12 papers in Cancer Research. Recurrent topics in Wan-Ching Yen's work include Cancer Cells and Metastasis (12 papers), Retinoids in leukemia and cellular processes (10 papers) and Estrogen and related hormone effects (7 papers). Wan-Ching Yen is often cited by papers focused on Cancer Cells and Metastasis (12 papers), Retinoids in leukemia and cellular processes (10 papers) and Estrogen and related hormone effects (7 papers). Wan-Ching Yen collaborates with scholars based in United States and Taiwan. Wan-Ching Yen's co-authors include William W. Lamph, Timothy Hoey, Austin Gurney, John Lewicki, Marcus Fischer, Ann M. Kapoun, Fumiko Axelrod, Aaron K. Sato, A. Negro‐Vilar and Reid P. Bissonnette and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Wan-Ching Yen

46 papers receiving 1.3k citations

Peers

Wan-Ching Yen

ONCOL

IMMUN

GENET

Kideok Jin United States

Tien-Chi Pan United States

Zu‐De Xu China

Nino Keshelava United States

Sophie North France

Ylenia Lombardo United Kingdom

Kelly A. Avery‐Kiejda Australia

Jane D. Holland Germany

Karuppiah Kannan United States

Veronica Catalano Italy

Kideok Jin United States

Wan-Ching Yen

864 ×0.9

580 ×1.0

ONCOL

310 ×1.3

176 ×1.3

IMMUN

121 ×0.9

GENET

Citations per year, relative to Wan-Ching Yen Wan-Ching Yen (= 1×) peers Kideok Jin

Countries citing papers authored by Wan-Ching Yen

Since Specialization

Citations

This map shows the geographic impact of Wan-Ching Yen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wan-Ching Yen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wan-Ching Yen more than expected).

Fields of papers citing papers by Wan-Ching Yen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wan-Ching Yen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wan-Ching Yen. The network helps show where Wan-Ching Yen may publish in the future.

Co-authorship network of co-authors of Wan-Ching Yen

This figure shows the co-authorship network connecting the top 25 collaborators of Wan-Ching Yen. A scholar is included among the top collaborators of Wan-Ching Yen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wan-Ching Yen. Wan-Ching Yen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Peng, Yi‐Hui, Mu‐Chun Li, Wan-Ching Yen, et al.. (2025). Structure-Based Design of Potent and Selective MerTK Inhibitors by Modulating the Conformation of αC Helix. Journal of Medicinal Chemistry. 68(11). 10877–10896.

Morales, David L.S., Wan-Ching Yen, Nicholas H. Perotti, et al.. (2025). Investigational New Drug-enabling studies to use genetically modified mesenchymal stromal cells in patients with critical limb ischemia. Stem Cells Translational Medicine. 14(2). 2 indexed citations

Li, Mu‐Chun, J. Satyanarayana Reddy, Chih‐Ming Chen, et al.. (2024). Discovery of Dual MER/AXL Kinase Inhibitors as Bifunctional Small Molecules for Inhibiting Tumor Growth and Enhancing Tumor Immune Microenvironment. Journal of Medicinal Chemistry. 67(13). 10906–10927. 3 indexed citations

Wang, Kai‐Hung, et al.. (2022). Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma. Journal of Biomedical Science. 29(1). 5–5. 14 indexed citations

Yen, Wan-Ching, Wen‐Hsing Lin, Yu‐Chieh Su, et al.. (2021). Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor Model. Journal of Medicinal Chemistry. 64(19). 14477–14497. 30 indexed citations

Yen, Wan-Ching, et al.. (2019). Inhibition of Rspo-Wnt pathway facilitates checkpoint blockade therapy by anti-RSPO3 antibody (DBPR117). Annals of Oncology. 30. v191–v191. 1 indexed citations

Fischer, Marcus, Vincent Yeung, Fiore Cattaruzza, et al.. (2017). RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutations. Scientific Reports. 7(1). 15270–15270. 37 indexed citations

Fischer, Marcus, Belinda Cancilla, Vincent Yeung, et al.. (2017). WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death. Science Advances. 3(6). e1700090–e1700090. 122 indexed citations

Yen, Wan-Ching, Marcus Fischer, Fumiko Axelrod, et al.. (2015). Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency. Clinical Cancer Research. 21(9). 2084–2095. 195 indexed citations

10.

O’Reilly, Eileen M., Lon Smith, Johanna C. Bendell, et al.. (2015). Final results of phase Ib of anticancer stem cell antibody tarextumab (OMP-59R5, TRXT, anti-Notch 2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).. Journal of Clinical Oncology. 33(3_suppl). 278–278. 10 indexed citations

11.

Cattaruzza, Fiore, Wan-Ching Yen, Alayne Brunner, et al.. (2015). Abstract 4367: Discovery and evaluation of pharmacodynamic and predictive biomarkers for anti-RSPO3, a treatment that reduces tumor growth and cancer stem cell frequency in patient derived xenograft tumor models. Cancer Research. 75(15_Supplement). 4367–4367. 1 indexed citations

12.

Fischer, Marcus, Wan-Ching Yen, Ann M. Kapoun, et al.. (2010). Anti-DLL4 Inhibits Growth and Reduces Tumor-Initiating Cell Frequency in Colorectal Tumors with Oncogenic KRAS Mutations. Cancer Research. 71(5). 1520–1525. 100 indexed citations

13.

Hoey, Timothy, Wan-Ching Yen, Fumiko Axelrod, et al.. (2009). DLL4 Blockade Inhibits Tumor Growth and Reduces Tumor-Initiating Cell Frequency. Cell stem cell. 5(2). 168–177. 318 indexed citations

14.

Yen, Wan-Ching, et al.. (2007). Bexarotene (LGD1069, Targretin), a Selective Retinoid X Receptor Agonist, Prevents and Reverses Gemcitabine Resistance in NSCLC Cells by Modulating Gene Amplification. Cancer Research. 67(9). 4425–4433. 54 indexed citations

15.

Cesario, Rosemary M., et al.. (2005). Differentiation and growth inhibition mediated via the RXR:PPARγ heterodimer in colon cancer. Cancer Letters. 240(2). 225–233. 64 indexed citations

16.

Hermann, Thomas, et al.. (2005). The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells. Lung Cancer. 50(1). 9–18. 33 indexed citations

17.

Yen, Wan-Ching, Rene Prudente, & William W. Lamph. (2004). Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma. Breast Cancer Research and Treatment. 88(2). 141–148. 37 indexed citations

18.

Yen, Wan-Ching, et al.. (2004). A Selective Retinoid X Receptor Agonist Bexarotene (Targretin) Prevents and Overcomes Acquired Paclitaxel (Taxol) Resistance in Human Non–Small Cell Lung Cancer. Clinical Cancer Research. 10(24). 8656–8664. 56 indexed citations

19.

Yen, Wan-Ching & Jessie L.‐S. Au. (1997). Pharmacodynamic Evaluation of Mitomycin C Analog BMS-181174 for Potential use in Intravesical Bladder Cancer Therapy. Pharmaceutical Research. 14(2). 241–245. 2 indexed citations

20.

Yen, Wan-Ching, et al.. (1995). Role of Na+ in the asymmetric paracellular transport of 4-phenylazobenzyloxycarbonyl-L-Pro-L-Leu-Gly-L-Pro-D-Arg across rabbit colonic segments and Caco-2 cell monolayers.. Journal of Pharmacology and Experimental Therapeutics. 275(1). 114–119. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact